Crossmark

Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis

Crossref DOI link: https://doi.org/10.1186/s12876-022-02210-3

Published Online: 2022-03-25

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Choi, Na Ryung

Kim, Ju Yeon

Hong, Ji Hoon

Hur, Moon Haeng

Cho, Heejin

Park, Min Kyung

Kim, Jihye

Lee, Yun Bin

Cho, Eun Ju

Lee, Jeong-Hoon

Yu, Su Jong

Yoon, Jung-Hwan

Kim, Yoon Jun
License Information

Text and Data Mining valid from 2022-03-25

Version of Record valid from 2022-03-25
More Information

Article History

Received: 15 September 2021

Accepted: 11 March 2022

First Online: 25 March 2022

Declarations

:

: All methods of the study were conducted according to the guidelines contained within the Declaration of Helsinki. The Institutional Review Board of Seoul National University Hospital approved this retrospective study and informed consent was waived (Seoul National University College of Medicine/Seoul National University Hospital Institutional Review Board).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below